Evaluation of Four HbA1c Point-of-Care Devices Using International Quality Targets: Are They Fit for the Purpose? by Lenters-Westra, Erna & English, Emma
For Peer Review
 
 
 
 
 
 
Evaluation of four HbA1c Point of Care devices using 
international quality targets: are they fit for purpose? 
 
 
Journal: Journal of Diabetes Science and Technology 
Manuscript ID DST-18-0088.R3 
Manuscript Type: Symposium/Special Issue 
Date Submitted by the Author: 04-Jun-2018 
Complete List of Authors: Lenters-Westra, Erna; Isala, Clinical Chemistry 
English, Emma; University of East Anglia Faculty of Medicine and Health 
Sciences 
Keywords: Diabetes, HbA1c, Hb-variants, Point-of-Care, Sigma metrics 
Abstract: 
Background: Point of Care (POC) testing is becoming increasingly valuable 
in healthcare delivery and it is important that the devices used meet the 
same quality criteria as main laboratory analyzers. Whilst External Quality 
Assessments provide a great tool for assessing quality, many POC devices 
are not enrolled in these schemes and standard laboratory evaluations are 
needed to assess performance.  
Methods: The Clinical and Laboratory Standards Institute (CLSI) protocols 
EP-5 and EP-9 were applied to investigate imprecision, accuracy and bias. 
We assessed bias using the mean of 4 certified Secondary Reference 
Measurement Procedures (SRMPs).    
Results: The Afiniontm2 and the Quo-Lab had CVs ≤ 3% in SI units and a 
bias ≤ 2 mmol/mol  at 48 and 75 mmol/mol. Sigma for the Afinion2 was 
5.8 and for the Quo-Lab 4.0. Both methods passed the NGSP criteria with 2 
instruments when compared with 4 individual SRMPs. The HbA1c 501 had a 
CV of 3.4% and 2.7% and a bias ≤2.4 mmol/mol and passed the NGSP 
criteria with 2 instruments compared with 4 individual SRMPs except for 
instrument 2 compared with the Tosoh G8. Sigma was 2.1. The A1Care 
had a sigma of 1.4 and failed all criteria mainly due to a high CV (6.2% at 
48 mmol/mol and 4.1% at 75 mmol/mol).  
Conclusions: The analytical performance was excellent for the Afinion2 and 
the Quo-Lab, acceptable for the HbA1c 501 and unacceptable for the 
A1Care according to different used criteria, demonstrating that whilst 
performance is improving there are still areas for considerable 
improvement  
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Abstract 
 
Background: Point of Care (POC) testing is becoming increasingly valuable in 
healthcare delivery and it is important that the devices used meet the same quality 
criteria as main laboratory analyzers. Whilst External Quality Assessments (EQA) 
provide a great tool for assessing quality, many POC devices are not enrolled in 
these schemes and standard laboratory evaluations are needed to assess 
performance. 
Methods: The Clinical and Laboratory Standards Institute (CLSI) protocols EP-5 and 
EP-9 were applied to investigate imprecision, accuracy and bias. We assessed bias 
using the mean of 4 certified Secondary Reference Measurement Procedures 
(SRMPs).  
Results: The Afiniontm2 and the Quo-Lab had CVs of ≤ 1.7 and ≤ 2.4 % respectively 
in IFCC SI units (≤ 1.2 and ≤ 1.7% NGSP) and a bias ≤ 2 mmol/mol (≤ 0.2% NGSP) 
at 48 and 75 mmol/mol (6.5 and 9.0% NGSP). Sigma for the Afinion2 was 5.8 and for 
the Quo-Lab 4.0. Both methods passed the NGSP criteria with 2 instruments when 
compared with 4 individual SRMPs. The HbA1c 501 had a CV of 3.4% and 2.7% in 
IFCC SI units (2.1% and 1.7% NGSP) and a bias ≤ 2.4 mmol/mol (≤ 0.2% NGSP) 
and passed the NGSP criteria with 2 instruments compared with 4 individual SRMPs 
except for instrument 2 compared with the Tosoh G8. Sigma was 2.1. The A1Care 
had a sigma of 1.4 and failed all criteria mainly due to a high CV ((6.2% and 4.1% in 
IFCC SI units (4.1% and 2.9% NGSP) at 48 and 75 mmol/mol (6.5 and 9.0% NGSP)).   
Conclusions: The analytical performance was excellent for the Afinion2 and the 
Quo-Lab, acceptable for the HbA1c 501 and unacceptable for the A1Care according 
to different used criteria, demonstrating that whilst performance is improving there 
are still areas for considerable improvement 
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Introduction: 
 
Point of care testing (POCT) provides rapid test results facilitating treatment 
decisions to be made in a single visit to the doctor’s office and thus, potentially 
improving the patient’s experience and outcomes (1-3). Currently there are in excess 
of 30 HbA1c POC instruments on the market. Many of these systems will have 
achieved certification that they are fit for purpose as a point of care test from 
whichever regulatory body controls distribution of the instrument in a particular 
country or region (for example; CE (conforms with relevant EU directives regarding 
health and safety or environmental protection), US Food and Drug Administration 
(FDA), NGSP,). However the evaluation of these instruments, to meet the relevant 
certification criteria, is generally performed by the manufacturers and under ideal 
conditions, which does not reflect real-life performance in the field (4). External 
Quality Assessments (EQA) with accu acy based value assignment is the ideal way 
to investigate the real analytical performance of a method in the hands of the 
end/intended users. Unfortunately many users of POC instruments do not participate 
in EQA schemes for various reasons such as cost, lack of legislative requirement and 
waiver programs that allow less stringent monitoring approaches, and therefore the 
real analytical performance of these instruments is not clearly defined (5). To further 
compound this issue some devices are designed in a such a way that internal quality 
control (IQC) is hard to undertake routinely and is a particular issue with single use 
test kits, giving even less information on the performance of these devices. 
In 2015 the IFCC Task Force for the implementation of the standardization of HbA1c 
published performance criteria for HbA1c methods based on sigma metrics (6). The 
criteria focus on CV and bias at a concentration of 50 mmol/mol (6.7% NGSP) as this 
is “in between two important medical decision points” ((48 mmol/mol (6.5% NGSP) 
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and 53 mmol/mol (7.0% NGSP)). More detailed evaluations may also focus on a 
wider range of HbA1c values. The NGSP manufacturer certification criteria focuses 
on relative differences between the test instrument compared with a single NGSP 
SRMP and not directly on imprecision (7).  
The European Reference Laboratory for Glycohemglobin (ERL) provides 
manufacturers with reference materials and also assists in performing evaluation 
studies for medical devices to provide an independent review of the analytical 
performance of an instrument. The ERL works with manufacturers to assess quality 
and advise on improvements at all stages of the development process and preferably 
before a new device comes to the market. The ERL can, for example, provide the 
manufacturer with reference materials or patient samples with values assigned by a 
reference method, to aid in calibration and performance analysis.  
The ERL has undertaken many evaluations of different HbA1c methods over the 
years and have developed additional performance criteria to enhance the evaluation 
of HbA1c instruments (8).  
The aim of this study was to evaluate 4 POC instruments according to the CLSI 
protocols and determine how the instruments perform when different criteria are 
applied using 4 certified IFCC and NGSP Secondary Reference Measurement 
Procedures (SRMPs) (9, 10). Additionally, we investigated the presence of potential 
interference from common Hb-variants on the instruments that were capable of 
analyzing frozen material and if there was a statistical difference between 2 
instruments of the same manufacturer.  
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Methods 
 
Pre-study 
Before starting with a full evaluation a small pre-study was undertaken to gain an 
overview of the analytical performance of each POC instrument. The pre-study 
consisted of analyzing 12 fresh patient samples in duplicate on one day and 
calculation of a %CV from the duplicates values were assigned using 4 IFCC and/or 
NGSP Certified Secondary Reference Measurement Procedures (SRMPs): 
• Roche Tina-quant Gen.3 HbA1c on Cobas c513, immunoassay, IFCC and 
NGSP SRMPs  (Roche Diagnostics, Rotkreuz, Switzerland); 
• Premier Hb9210, affinity chromatography HPLC, IFCC and NGSP SRMPs 
Biotech, Bray, Ireland); 
• Tosoh G8, cation-exchange HPLC, IFCC SRMP (Tosoh Bioscience, 
Tessenderlo, Belgium) and 
• Abbott Enzymatic method on Architect c4000, IFCC and NGSP SRMPs 
(Abbott Diagnostics, Lake Forest, US). 
The results of the pre-study were provided to the individual manufacturers, who then 
decided whether or not to proceed to a full evaluation (EP-5, EP-9, Hb-variant 
interference, etc.). The manufacturer can then either choose to use the data internally 
or to sign a contract with the ERL to publish the results. The decision to publish or not 
must be made prior to starting a full evaluation. The following 4 manufacturers, gave 
permission to use the results for publication: 
• The AfinionTM 2 (Abbott, Oslo, Norway), which is based on boronate affinity 
separation, with results available in 3 min. This instrument is the successor of 
the Alere Afinion AS100 Analyzer. The difference between the AS100 
Analyzer and the Afinion2 is that the Afinion2 instrument has a built-in 
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connectivity unit and a new lid design. The user interface, the assays and the 
test procedure is the same as for the AS100 Analyzer. 
• The Quo-Lab (EKF Diagnostics PLC, Cardiff UK), is based on boronate 
affinity separation and the use of fluorescence quenching with results 
available in under 4 min.  
• The HbA1c 501 (HemoCue Diagnostics, Ängelholm, Sweden), is based on 
boronate affinity separation with results available in 5 min. 
• The A1Care (i-SENSE, Seoul, Korea), which is based on enzymatic 
determination of HbA1c with results available in 5 min. 
 
Full evaluation: 
Imprecision: 
The CLSI EP-5 protocol was used to investigate assay imprecision (11). Aliquots 
were made from two patient samples and stored at minus 80 °C degrees until 
analysis (duplicate measurements twice a day for 20 days). The Afinion2 cannot 
utilize hemolyzed material so two fresh patient samples with an HbA1c value of 
approximately 48 mmol/mol and 75 mmol/mol were stored in the refrigerator for 14 
days. Every day the samples were mixed and 200ul was taken from the original tube 
and put into a small cup for analysis 2 times a day in duplicate for 14 days. CVs were 
also calculated on the basis of the duplicates of the fresh patient samples in the EP-9 
protocol.  
 
Accuracy and method comparison: 
The CLSI EP-9 protocol was performed on two separate instruments from each 
manufacturer – the aim was to assess the quality of the instrument as a whole rather 
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than just using different reagent lot numbers on one instrument. Whilst reagent 
variability between lot numbers is a key factor in analytical performance, using two 
instruments will mimic the ‘between laboratory’ performance of these analyzers. 
The CLSI EP-9 protocol was performed with 40 fresh patient samples with 2  
instruments and the data were used to investigate the bias between the POC 
instruments and the 4 SRMPs as used in the pre-study (n=40, 8 samples per day for 
5 days, duplicate measurements) (12).  
The data were also used to calculate performance against the NGSP certification 
criteria (7). To assess overall calibration and bias independently of the chosen 
SRMP, the results of the POC instruments in the EP-9 procedure were compared 
with the mean of the 4 SRMPs.  
Medical Decision Point (MDP) analysis was performed at an HbA1c value of 48 and 
75 mmol/mol (6.5% and 9.0% NGSP). When 2 methods are statistically identical, the 
95% CI for each y MDP includes the corresponding x MDP. For example: 48 
mmol/mol (6.5% NGSP), the diagnostic cut-off value for the diagnosis of diabetes 
falls within  46.0 mmol/mol (6.4% NGSP) to 49.5 mmol/mol (6.7% NGSP), the 95% 
CI around the calculated y, so both methods are statistically identical.  
The bias at 48 mmol/mol and the CV at the same concentration in EP-5 were used to 
calculate sigma.  
 
Analytical performance criteria 
 
Sigma metrics 
Total Allowable Error (TAE) for HbA1c has been set by the IFCC Task Force on 
Implementation of HbA1c standardization as a default of 5 mmol/mol (0.46% NGSP) 
at an HbA1c level of 50 mmol/mol (6.7% NGSP) which corresponds with a relative 
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TAE of 10% ((5/50)*100%) in SI units (6.9% NGSP units ((0.46/6.7)*100%)) with risk 
levels of 2σ for routine laboratories and 4σ for laboratories performing clinical trials 
(6). 
 
NGSP Manufacturer Certification Criteria 
Thirty seven of 40 results need to be within 6% (relative) of an individual NGSP 
SRMP to pass certification (7). 
 
Enhanced precision and bias criteria for a full evaluation done at ERL: 
1. CV in EP-5 at 48 mmol/mol and 75 mmol/mol: ≤3.0% in SI units  (≤2.0% in NGSP 
units). 
2. Bias compared with the mean of at least 3 SRMPs at 48 and 75 mmol/mol (6.5% 
and 9.0% NGSP): ≤2.0 mmol/mol (≤0.2% NGSP) (8). 
 
Statistical Significant Difference between instruments 
The EP-9 results of both instruments have been used to test if the slope, intercept 
and MDPs were different (outside the 95% CI) between the 2 instruments. In other 
words, two instruments can be considered statistically identical if: 
• The slope is 1.00 (within 95% confidence) 
• The intercept is 0.00 (within 95% confidence) 
• The predicted Y MDPs are equal to the X MDPs (within 95% confidence) 
 
Statistical calculations: 
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Calculations were performed using Microsoft® Excel 2010 (Microsoft Corporation). 
Statistical analyses were performed using Analyse-It® (Analyse-It Software) and EP 
Evaluator Release 9 (Data Innovations LLC) (13). 
For the duplicates in the EP-9 protocol, CV was calculated with the following formula: 
 
 CVa =
(∆)2∑
n
x 2
 × 100%  
 
where CVa is the analytical CV, ∆ is the difference between duplicates, n is the 
number of duplicates, and x  is the mean of the duplicates. 
Sigma was calculated using the formula: σ=(TAE – Bias)/CV were the Total 
Allowable Error (TAE) was 10%.  
 
Interference of Hb-variants: 
Twenty non-variant samples (HbAA), 10 HbAS, 10 HbAC, 10 HbAD, 10 HbAE, 10 
HbF and 9 elevated A2 samples were analyzed on 3 different days. Due to a lack of 
cartridges with the same lot number for the Quo-Lab, we analyzed 20 HbAA,  9 
HbAS, 9 HbAC, 9 HbAD, 9 HbAE, 5 HbF and 4 elevated A2 samples. Both the 
normal and Hb-variant samples were stored at -80°C until analysis. Specific variants 
were identified using cation-exchange HPLC (Menarini HA8180V, Diabetes Mode) 
and confirmed with capillary electrophoresis (Sebia Capillarys 2 Flex Piercing, 
Hemoglobin program). Percentage HbF (3.2, 4.6, 6.2, 6.9, 8.6, 11.0, 13.0, 16.5, 18.0 
and 34.0%)  was determined using the Sebia Capillarys 2 Flex Piercing Hemoglobin 
program. HbA1c values for samples with Hb variants were assigned using IFCC 
calibrated boronate affinity HPLC (Premier Hb9210). For samples with increased 
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HbF, HbA1c values were assigned using IFCC calibrated cation-exchange HPLC 
(Menarini HA8180V, Diabetes Mode).  
As a guide, one could say that the investigated Hb variant can be considered as not 
causing a clinically relevant interference if the results of the Hb variant fall within a 
defined scatter line of ±10% (IFCC units) of  the regression line derived from the 
comparison of the test instrument and the IFCC assigned values of the non-variant 
samples (HbAA). Whilst this is a guide rather than an absolute, by graphing this 
relationship  it is a simple way to identify patterns of interference (14).  
 
Results 
 
Imprecision studies 
The imprecision results of the EP-5 protocol and calculated from the duplicates of the 
samples in EP-9 are detailed in Table 1. The Afinion2 and the Quo-Lab passed the 
criteria of having a CV ≤ 3% (≤ at 2.0% NGSP) at 48 and 75 mmol/mol (6.5% and 
9.0% NGSP) and calculated from the duplicates in EP-9. The CV of the HbA1c 501 at 
48 mmol/mol (6.5% NGSP) was just above the criteria (3.4% IFCC SI units (2.1% 
NGSP)) but passed it at an HbA1c value of 75 mmol/mol (9.0% NGSP) and from the 
duplicates in EP-9. The A1Care failed the criteria at both HbA1c values in EP-5 and 
calculated from the duplicates in EP-9. 
Method comparisons 
Figure 1A-D shows the EP-9 results of the 4 POC instruments compared to the mean 
of the 4 SRMPs with 2 different instruments. Table 2 shows the NGSP certification 
pass/fail with respect to the individual SRMPs using the results of the EP-9 protocol. 
The bias at 48 (6.5% NGSP) and 75 mmol/mol (9.0% NGSP) of all 4 POC 
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instruments was ≤ 2 mmol/mol (≤ 0.2% NGSP) compared to the mean of the 4 
SRMPs except for HbA1c 501 instrument 2 at 75 mmol/mol (9.0% NGSP) (bias was 
2.4 mmol/mol (0.2% NGSP) (Table 3). However, instrument 2 of the A1Care gave 
lower results in the low area and higher results in the high area resulting in a mean 
bias of < 2 mmol/mol (< 0.2% NGSP) ( (Figure 1D).  
 
Statistical Significant Difference between instruments 
There was a statistically significant difference in IFCC SI units between the 2 
instruments for the Quo-Lab (Y=1.04X (95% CI: 1.02 to 1.06) -1.9 (95% CI: -3.0 to -
0.8) and the A1Care (Y=1.10X (95% CI: 1.05 to 1.16) -5.8 (95% CI: -8.9 to -2.7) and 
no significant difference between the 2 instruments for the Afinion2  (Y=1.00X (95% 
CI: 0.98 to 1.01) + 0.3 (95% CI: -0.5 to 1.1) and the HbA1c 501 (Y=1.00X (95 CI: 0.98 
to 1.03) – 0.3 (95% CI: -1.8 to 1.3). 
 
Interference of Hb-variants 
The 3 investigated instruments showed no consistent clinically significant interference 
from HbAS, HbAC, HbAD, HbAE, elevated A2 (Figure 2A-C). There were some 
outliers, in particular for the A1cCare (Figure 2C) however these may have been due 
to the high CV observed with this instrument. Table 4 shows the mean relative 
difference for the different Hb-variants except for HbF as the mean relative difference 
cannot be calculated since the interference is level-dependent (%HbF). In each case 
it is clear that high levels of HbF (>34% HbF ) appear to interfere with measurement 
of HbA1c however exact thresholds cannot be determined from this dataset. Results 
were corrected for bias based on the bias found in the non-variant samples (HbAA) 
when calculating the mean relative difference (Table 4). 
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Analytical Performance Criteria 
Figure 3 shows the combined results of EP-5 and EP-9 in sigma metrics at 48 
mmol/mol (6.5% NGSP) for instrument 1. Sigma for the Afinion2 was 5.8, Quo-Lab 
4.0, HbA1c 501 2.1 and A1Care 1.4.  
Table 5 summarizes the results for each of the different analytical performance 
criteria. The Afinon2 and the Quo-Lab passed all criteria. The HbA1c 501 passed 
most of the criteria but not all and the A1Care failed most of the criteria. 
 
Discussion 
 
In 2009 we investigated 8 different POC instruments and four years later we 
investigated again 7 different POC instruments (15, 16). The analytical performance 
of HbA1c POC instruments investigated in 2013 improved considerably compared to 
the analytical performance of HbA1c POC instruments in 2009. The poor results of 
the first study along with greater collaboration with the IFCC and NGSP and 
sequential tightening of the NGSP certification and CAP EQA criteria may have acted 
as a “wakeup call” for some manufacturers to improve their methods and drive 
forward quality improvement. The impact of having poor quality performance 
highlighted in a peer-reviewed publication can have significant repercussions for 
manufacturers and may lead to reluctance or resistance to engaging in similar 
detailed quality studies. However these independent investigations are necessary to 
provide health professionals and their patients with confidence in the analytical 
equipment they are using. Some manufacturers may choose to withdraw their 
method from the market if they failed to improve the analytical performance and 
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some improved their methods by working together with the ERL. The publication in 
2009 showed that some methods (Quo-Test, Quo-Lab and InnovaStar) had problems 
with IFCC frozen reference material (16). This frozen reference material was not 
commutable with these methods. After the publication the manufacturer of the Quo-
test and Quo-Lab contacted the ERL and currently every week samples with 
assigned values are send to the manufacturer which are used by the manufacturer to 
calibrate or check the new produced cartridges. In this study we evaluated the Quo-
Lab again and the results showed that the Quo-Lab met all criteria and that there is 
hardly any bias between the Quo-Lab and the mean of the 4 SRMPs (Table 5). Also 
the Quo-Test (not evaluated in this study) which is from the same manufacturer, has 
no bias anymore compared to the mean of 3 SRMPs (17). The Afinion2 met all 
criteria and precision has improved compared to previous studies. In the past the 
CVs obtained with controls were not in line with the CVs calculated from the 
duplicates in EP-9 (15, 16). The controls gave lower CVs than the CVs calculated 
from real patient blood. For this reason we used in this study fresh patient blood for 
14 days. The CVs in this study were all ≤ 1.7% in SI units (≤ 1.2 NGSP) (Table 1)  
while the CV in the 2014 study calculated from the duplicates in EP-9 was  3.0% in SI 
units (2.0% NGSP), demonstrating an improvement in quality since the previous 
study (16). As frozen or hemolyzed material is not commutable with the Affinion2 
system, samples with values assigned by an SRMP are sent to the company on a 
regular basis for calibration and/or check of the cartridges. This is likely to account for  
both methods (Afinion2 and Quo-Lab) show excellent result with the method 
comparisons (Figure 1A and 1B) 
The HbA1c 501 had a borderline analytical performance. The CV at an HbA1c value 
of 48 mmol/mol (6.5% NGSP) was high (3.4% in SI units, 2.1% in NGSP units) and 
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the calibration of the instrument needs a small adjustment (+1.7 mmol/mol higher 
results (+0.2% NGSP). However, it passed the sigma metrics criteria for routine 
laboratory (σ was 2.1). 
The A1Care did not meet any criteria mainly due to the high imprecision (CV was 
6.2% (4.1% NGSP) at 47 mmol/mol (6.4% NGSP) and 4.1% (2.9% NGSP) at 71 
mmol/mol (8.7% NGSP). The instrument also gave often an error (error rate of 6.3%). 
The A1Care gave numerous incorrect results which were too frequent to be 
considered outliers. The A1Care also failed the NGSP criteria compared with the 4 
individual SRMPs for both instruments and there was a significant statistical 
difference between the 2 instruments, especially in the low area. This was quite a 
surprise as the A1Care has a NGSP manufacturer certificate obtained in January 
2018 (18). The outliers seen in our study may be as a result of a technical problem 
within the instruments or damage incurred during transport. A closer inspection of the 
results in the EP-9 study showed that one of the two results (duplicate measurement) 
was consistently in line with the reference method and one result was a complete 
outlier. This along with the high percentage of errors may be a sign of a technical 
problem with the instrument and serves to highlight the need to assess all aspects of 
the analytical process where possible. As the same reagent lot numbers were used 
on each instrument this data serves to demonstrate that it is not only reagent lot 
variability that can be a major contributing factor to poor performance and a holistic 
approach to assessing quality is needed. The poor precision of the method may 
mask errors in the bias/calibration as can be seen in the MPD analysis. The 95% CI 
around the MDPs of 48 and 75 mmol/mol (6.5% and 9.0% NGSP) was so large that 
there was no statistical significant difference between the mean of the 4 SRMPs and 
instrument 1 at 48 and 75 mmol/mol (6.5% and 9.0% NGSP) and instrument 2 at 75 
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mmol/mol (9.0% NGSP). This means that large differences between methods are 
more likely to be statistically significant when methods are precise, and conversely, 
the less precise a method is, the easier it is to be not statistically different to a 
reference method. Therefore it is necessary to look closely at both imprecision and 
bias when evaluating methods.   
The 3 investigated POC instruments did not show clinically significant interference of 
common Hb-variants and ß-Thalassemia (Table 4).  Samples with high percentages 
of HbF can only be accurately measured with methods that can separate HbF from 
total hemoglobin (generally cation exchange HPLC and capillary electrophoresis 
based methods) which is not the case with immunoassay, enzymatic and affinity 
based methods which may result in a falsely low HbA1c result (19). This also seems 
to apply to the 3 investigated POC instruments at higher levels of HbF. The Afinion2 
was not tested for interference of common Hb-variants as this method cannot utilize 
frozen material. However, 2 studies in the past showed that there is no interference 
of HbAS, HbAC, HbAD and HbAE (20, 21). EQA data reveals the real analytical 
performance of HbA1c POC instruments as results are produced by end/intended 
users using different lot numbers and different instruments. A possible reason why 
the Afinion and the DCA Vantage have such a big market share in HbA1c POC could 
be because the manufacturers of these POC instruments can prove with EQA data 
that the analytical performance of these instruments is equal to laboratory based 
HbA1c methods and that it can be used for the diagnosis of diabetes (22). 
Participation in EQA schemes should be mandatory for users of POC instruments to 
assure quality.   
Evaluation done at ERL is more independent than a certification done at the 
manufacturers site but still has its limitations. The limitations of our study was that 
Page 16 of 33
https://mc.manuscriptcentral.com/jofdst
Journal of Diabetes Science and Technology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
15 
 
this was a single center with one reagent lot number and an experienced technician. 
However, the novelty of the study is that two instruments were used from each 
manufacturer, with the same reagent lot numbers, effectively demonstrating how the 
instruments can perform between laboratories. 
Conclusions 
The analytical performance of point of care instruments for HbA1c can be seen to be 
continually improving. However, there are still some instrument that do not perform to 
the desired level when different quality targets are applied. In order to improve 
access to health care and increase the efficacy of the service provided to patients, 
POC is likely to play an increasing role in health care delivery in the future. For this 
reason it is important to ensure that instruments meet the same quality criteria as 
main laboratory analyzers and that there is a continual drive for quality improvement. 
Whilst robust evaluations such as those described in this paper are invaluable in 
assisting decision making when choosing a device, enrolment in EQA schemes is 
also an integral part of monitoring the performance of instruments in their relevant 
clinical settings. 
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Legends 
 
Figure 1  
HbA1c results in SI units for two different instruments from (A) Afinion2, (B) Quo-Lab, 
(C) HbA1c 501 and (D) A1Care point-of-care instruments compared to the mean 
HbA1c results from 4 SRMPs. 
 
Figure caption: 
line of identity (x=y) 
     -------  ± 10% 
 
Figure 2  
Interference of common Hb-variants of Quo-Lab (A), HbA1c 501 (B)  and A1Care (C).  
Figure caption: 
line of HbAA samples 
     -------  ± 10% 
 
Figure 3  
Sigma metrics results for the Afinion2 (A ), Quo-Test (B), HbA1c 501 (C ) and 
A1Care (D) based on the CV in EP-5 at 48 mmol/mol and bias at 48 mmol/mol 
compared to the mean of 4 Secondary Reference Measurement Procedures. 
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Table 1 Imprecision results based on EP-5 and on the duplicates in EP-9 
 
   CV (%) SI units   CV(%) NGSP units 
 
Afinion2  1.7 (44 mmol/mol)$             1.2 (6.2%)$ 
   1.1 (74 mmol/mol)$   0.9 (9.0%)$ 
Instrument 1*  1.7     0.9  
Instrument 2*  1.7      0.9  
 
A1Care  6.2 (47 mmol/mol)   4.1 (6.4%) 
   4.1 (71 mmol/mol)   2.9 (8.7%) 
Instrument 1*  4.9      3.5  
Instrument 2*  5.0      3.5  
 
HbA1c 501  3.4 (46 mmol/mol)   2.1 (6.3%) 
   2.7 (72 mmol/mol)   1.7 (8.7%) 
Instrument 1*  2.1      1.5  
Instrument 2*  2.5      1.7  
 
Quo-Lab  2.4 (46 mmol/mol)   1.6 (6.4%) 
   2.4 (71 mmol/mol)   1.8 (8.6%) 
Instrument 1*  1.5     1.1  
Instrument 2*  1.9      1.3  
 
* Based on duplicates in EP-9 
$ Based on 14 days instead of 20 
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Table 2 EP-9 results in NGSP units and calculations of NGSP certification criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Shaded row means same measurement principle as investigated POC method 
* based on 35 samples instead of 40 
  
Deming regression lines  
Instrument 1 
 
Bias 
 
SEE 
Out    
± 6% 
SRM 
 
NGSP 
criteria 
 
Instrument 2 
 
Bias 
 
SEE 
Out    
± 6% 
SRM 
 
NGSP 
criteria 
Afinion2 (Y)     vs Premier (X) Y=0.94X + 0.43  0.01 0.09 0 Pass Y=0.94X + 0.43 -0.01 0.09 0 Pass 
                         vs Abbott (X) Y=0.95X + 0.38  0.01 0.15 1 Pass Y=0.95X + 0.35  0.01 0.14 1 Pass 
                         vs Tina-quant (X)  Y=0.96X + 0.29  0.03 0.16 1 Pass Y=0.98X + 0.22  0.04 0.14 1 Pass 
                         vs Tosoh G8 (X)  Y=0.95X + 0.27 -0.06 0.18 0 Pass Y=0.95X + 0.28 -0.05 0.19 1 Pass 
A1Care (Y)       vs Premier (X) Y=0.99X + 0.04 -0.07 0.34 9 Fail Y=1.07X – 0.56 -0.09 0.39 10 Fail 
                         vs Abbott (X) Y=0.99X + 0.05 -0.04 0.28 5 Fail Y=1.08X – 0.66 -0.08 0.33 7 Fail 
                         vs Tina-quant (X)  Y=1.00X – 0.00 -0.02 0.30 8 Fail Y=1.08X – 0.63 -0.06 0.31 7 Fail 
                         vs Tosoh G8 (X)  Y=0.99X – 0.06 -0.10 0.33 8 Fail Y=1.08X – 0.72 -0.13 0.34 9 Fail 
HbA1c 501 (Y) vs Premier (X) Y=0.97X + 0.10 -0.13 0.14 0 Pass Y=0.96X + 0.13* -0.15 0.13 0 Pass 
                         vs Abbott (X) Y=0.97X + 0.08 -0.11 0.21 1 Pass Y=0.96X + 0.14* -0.14 0.18 1 Pass 
                         vs Tina-quant (X)  Y=0.99X – 0.06 -0.08 0.22 2 Pass Y=0.98X + 0.05* -0.11 0.18 2 Pass 
                         vs Tosoh G8 (X)  Y=0.98X - 0.02 -0.17 0.23 1 Pass Y=0.96X + 0.11* -0.18 0.22 4 Fail 
Quo-Lab(Y)     vs Premier (X) Y=0.95X + 0.31 -0.04 0.14 0 Pass Y=1.00X – 0.01 -0.01 0.15 0 Pass 
                         vs Abbott (X) Y=0.97X + 0.24 -0.01 0.15 1 Pass Y=1.01X – 0.04  0.02 0.16 0 Pass 
                         vs Tina-quant (X)  Y=0.98X + 0.14  0.01 0.15 1 Pass Y=1.02X – 0.13  0.04 0.16 0 Pass 
                         vs Tosoh G8 (X)  Y=0.97X + 0.15 -0.08 0.20 3 Pass Y=1.01X – 0.14 -0.05 0.22 2 Pass 
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Table 3 Medical decision point analysis at 48 mmol/mol and 75 mmol/mol (in brackets the 95% CI) 
compared to the mean of the 4 SRMPs. 
 
 
 
  
Instrument 1 
 
 
Instrument 2 
 
 
Afinion2 
 
 
47.9 (47.6 – 48.2) 
 
73.7 (73.2 – 74.2)* 
 
48.0 (47.7 – 48.4) 
 
73.8 (73.3 – 74.3)* 
 
Quo-Lab 
 
 
47.8 (47.4 – 48.2) 
 
74.1 (73.6 – 74.7)* 
 
47.9 (47.5 – 48.4) 
 
75.4 (74.8 – 76.0) 
 
HbA1c 501 
 
 
46.6 (46.1 – 47.1)* 
 
73.3 (72.5 – 74.0)* 
 
46.5 (46.0 – 46.9)* 
 
72.6 (71.9 – 73.4)* 
 
A1Care 
 
 
47.5 (46.5 – 48.4) 
 
74.6 (73.2 – 76.0) 
 
46.4 (45.5 – 47.3)* 
 
76.3 (75.0 – 77.7) 
*statistically significant difference 
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Table 4 Mean relative difference (%) of the common Hb-variants (n=±10 per variant) compared to the assigned value. 
 
  
HbAS 
 
 
HbAC 
 
HbAD 
 
HbAE 
 
Elevated A2 
 
 
Quo-Lab 
 
 
-4.3 
 
2.2 
 
-2.5 
 
3.8 
 
0.9 
 
 
HbA1c 501 
 
 
-7.8 
 
6.3 
 
-6.7 
 
4.3 
 
4.7 
 
 
A1Care 
 
 
4.2 
 
2.7 
 
1.9 
 
0.5 
 
-0.6 
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Table 5 Overview of passing/failing of different criteria 
 
 
NT=not tested 
NA=Not applicable 
 
 
Criteria 
Afinion2 
Inst. 1 
Afinion2 
Instr. 2 
Quo-
Lab 
Instr. 1 
Quo-
Lab 
Instr. 2 
HbA1c 
501 
Instr. 1 
HbA1c 
501 
Instr. 2 
A1Care 
Instr.1 
A1Care 
Instr.2 
IFCC Task Force on HbA1c 
Standardization 
≥ 2 sigma at 50 mmol/mol 
 
Pass 
 
NT 
 
Pass 
 
NT 
 
Pass 
 
NT 
 
Fail 
 
NT 
NGSP manufacturer  
Premier Hb9210 
Roche TQ 
Tosoh G8 
Abbott Enzymatic 
        
Pass Pass Pass Pass Pass Pass Fail Fail 
Pass Pass Pass Pass Pass Pass Fail Fail 
Pass Pass Pass Pass Pass Fail Fail Fail 
Pass Pass Pass Pass Pass Pass Fail Fail 
Enhanced precision and bias criteria (see 
methods section for details) 
CV ≤ 3% at 48 mmol/mol 
CV ≤ 3% at 75 mmol/mol 
Bias ≤ 2 mmol/mol at 48 mmol/mol 
Bias ≤ 2 mmol/mol at 75 mmol/mol 
        
Pass NT Pass NT Fail NT Fail NT 
Pass NT Pass NT Pass NT Fail NT 
Pass Pass Pass Pass Pass Pass Pass Pass 
Pass Pass Pass Pass Pass Fail Pass Pass 
No Interference of Hb-variants NT NA Pass NA Pass NA Pass NA 
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Lenters Figure 1A  
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Lenters Figure 1B  
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Lenters Figure 1C  
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Lenters Figure 1D  
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